Skip to playerSkip to main content
  • 6 years ago
Suven Life Sciences has missed their target for SUVN 502 - a molecule which they were banking on for Alzheimers and outlicensing opportunity. Venkat Jasti, chairman and CEO of Suven Life Sciences shared more details and the future course of action.
Comments

Recommended